Bioporto A/S
CSE:BIOPOR

Watchlist Manager
Bioporto A/S Logo
Bioporto A/S
CSE:BIOPOR
Watchlist
Price: 1.616 DKK -1.1% Market Closed
Market Cap: 694.3m DKK
Have any thoughts about
Bioporto A/S?
Write Note

Bioporto A/S
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bioporto A/S
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Bioporto A/S
CSE:BIOPOR
Free Cash Flow
-kr56m
CAGR 3-Years
-5%
CAGR 5-Years
-4%
CAGR 10-Years
-13%
Genmab A/S
CSE:GMAB
Free Cash Flow
kr6.5B
CAGR 3-Years
5%
CAGR 5-Years
53%
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Free Cash Flow
-kr711.4m
CAGR 3-Years
16%
CAGR 5-Years
-12%
CAGR 10-Years
-29%
Ascendis Pharma A/S
NASDAQ:ASND
Free Cash Flow
-€262.5m
CAGR 3-Years
14%
CAGR 5-Years
-9%
CAGR 10-Years
-33%
B
Bavarian Nordic A/S
CSE:BAVA
Free Cash Flow
kr882.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
F
Fluoguide AS
STO:FLUO
Free Cash Flow
-kr31.8m
CAGR 3-Years
-53%
CAGR 5-Years
-667%
CAGR 10-Years
N/A
No Stocks Found

Bioporto A/S
Glance View

Market Cap
694.3m DKK
Industry
Biotechnology

Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

BIOPOR Intrinsic Value
1.251 DKK
Overvaluation 23%
Intrinsic Value
Price

See Also

What is Bioporto A/S's Free Cash Flow?
Free Cash Flow
-56m DKK

Based on the financial report for Jun 30, 2024, Bioporto A/S's Free Cash Flow amounts to -56m DKK.

What is Bioporto A/S's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-13%

Over the last year, the Free Cash Flow growth was 11%. The average annual Free Cash Flow growth rates for Bioporto A/S have been -5% over the past three years , -4% over the past five years , and -13% over the past ten years .

Back to Top